Unlocking the Potential of High Affinity Immunoglobulin Epsilon Fc Receptor (FcERI) as a Drug Target and Biomarker

Target Name: High Affinity Immunoglobulin Epsilon Fc Receptor

NCBI ID: P33691

High Affinity Immunoglobulin Epsilon Fc Receptor

Other Name(s): FcERI | Fc-epsilon RI

Unlocking the Potential of High Affinity Immunoglobulin Epsilon Fc Receptor (FcERI) as a Drug Target and Biomarker

Introduction

Immunoglobulin Epsilon Fc receptor (FcERI) is a type of protein that plays a crucial role in the immune system. It is a high affinity receptor that is expressed in various tissues and cells, including the placenta, fetal liver, and human capital domain (HepG2 ) cells. FcERI has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

High Affinity Immunoglobulin Epsilon Fc Receptor (FcERI)

FcERI is a type of transmembrane protein that is composed of two constant (伪 and 尾) and two variable (纬 and delta) regions. It has a molecular weight of approximately 180 kDa and a calculated pI of approximately 1.5 nM. FcERI is expressed in various tissues and cells, including the placenta, fetal liver, and human capital domain (HepG2) cells. It is highly predictive of the response to various treatments, including cancer chemotherapy, and has been used as a biomarker for various diseases.

Potential Drug Target

FcERI has been identified as a potential drug target due to its unique structure and its expression in various tissues. FcERI has a high affinity for small molecules, which makes it an attractive target for small molecule inhibitors. Additionally, its expression is often reduced in various diseases, including cancer, which suggests that targeting FcERI may have potential therapeutic benefits.

FcERI has been shown to play a role in various cellular processes, including cell adhesion, migration, and angiogenesis. It has also been shown to be involved in the regulation of inflammation and immune responses. Several studies have suggested that targeting FcERI may have therapeutic potential benefits for various diseases, including cancer.

Biomarker

FcERI has also been identified as a potential biomarker for various diseases. Its expression is often reduced in various diseases, including cancer, which suggests that targeting FcERI may have potential diagnostic benefits. Additionally, FcERI has been shown to be involved in the regulation of inflammation and immune responses, which may be useful as a biomarker for autoimmune disorders.

Methods

To determine the potential drug targets and biomarkers for FcERI, several approaches have been taken. Firstly, several small molecules have been shown to interact with FcERI and have the potential to be inhibitors. Secondly, several studies have been conducted to determine the expression and function of FcERI in various tissues and cells. Thirdly, several studies have been conducted to determine the potential therapeutic benefits of targeting FcERI.

Conclusion

High Affinity Immunoglobulin Epsilon Fc Receptor (FcERI) is a protein that has the potential to be a drug target and biomarker for various diseases. Its unique structure and high affinity for small molecules make it an attractive target for small molecule inhibitors. Additionally, its expression is often reduced in various diseases, which suggests that targeting FcERI may have potential therapeutic benefits. Further research is needed to fully understand the role of FcERI as a drug target and biomarker for various diseases.

Protein Name: High Affinity Immunoglobulin Epsilon Fc Receptor

The "High Affinity Immunoglobulin Epsilon Fc Receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about High Affinity Immunoglobulin Epsilon Fc Receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets